Skip to main content
Clinical Trials/NCT01601964
NCT01601964
Completed
Not Applicable

Vascular Endothelial Growth Factor Levels in Ectopic Pregnancy

Bagcilar Training and Research Hospital1 site in 1 country30 target enrollmentMay 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Complication Following Ectopic Pregnancy
Sponsor
Bagcilar Training and Research Hospital
Enrollment
30
Locations
1
Primary Endpoint
The primary Outcome Measure of this study is to determine plasma Vascular Endothelial Growth Factor cut-off level in patient with ectopic pregnancy who needs to surgical treatment.
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

The aim of this study is to determine plasma Vascular Endothelial Growth Factor level and change in patient with ectopic pregnancy who needs to surgical treatment.

Patient with ectopic pregnancy diagnosed and treated with medically or surgically will be included in the study. This is an observational study.The plasma Vascular Endothelial Growth Factor level will be measured first day and two day after the diagnosis of ectopic pregnancy.

Detailed Description

This study is a prospective, observational, single-center study. Ethical approval was obtained from the Institutional Review Board. This study will be completed with 30 patients with ectopic pregnancy. An intervenous cannula will be centrifuged for 15 minutes at 1000 g within 30 minutes of collection. Aliquots of plasma will be added to eppendorf tubes and stored at -20°C. Plasma Vascular Endothelial Growth Factor levels will be measured using a Human VEGF-A Platinum ELISA kit (bioscience company, Catalog No: 00122, Santa Clara, California, USA). All assays will be performed according to the manufacturer's instructions. The test kit sensitivity is 2.5 pg/ml. Intracycle variability is %4-6, intercycle variability is %8-10.

Registry
clinicaltrials.gov
Start Date
May 2012
End Date
February 2013
Last Updated
10 years ago
Study Type
Observational
Sex
Female

Investigators

Sponsor
Bagcilar Training and Research Hospital
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients who suspected ectopic pregnancy

Exclusion Criteria

  • hemodynamically unstable patient
  • healthy pregnancy (a healthy increase in ß HCG)
  • missed abortion
  • incomplete abortion
  • The patient who need immediate surgical treatment

Outcomes

Primary Outcomes

The primary Outcome Measure of this study is to determine plasma Vascular Endothelial Growth Factor cut-off level in patient with ectopic pregnancy who needs to surgical treatment.

Time Frame: 3-4 months

Study Sites (1)

Loading locations...

Similar Trials